Sanofi makes $3.2 bln offer for US mRNA partner Translate Bio | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Monday
June 02, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
MONDAY, JUNE 02, 2025
Sanofi makes $3.2 bln offer for US mRNA partner Translate Bio

Global Economy

Reuters
03 August, 2021, 12:25 pm
Last modified: 03 August, 2021, 12:29 pm

Related News

  • Novavax signs Covid-19 license deal with Sanofi, removes doubt about business viability
  • Healthcare companies Sanofi and GSK to seek Covid-19 vaccine regulatory approval
  • Beximco Pharma completes Sanofi acquisition
  • France's Sanofi halts work on mRNA Covid vaccine
  • Beximco Pharma inks Sanofi acquisition deal

Sanofi makes $3.2 bln offer for US mRNA partner Translate Bio

Translate Bio's shares surged on Monday following the Reuters report. Sanofi's offer of $38 represents a 30.4% premium to Translate Bio's August 2 closing price of $29.15

Reuters
03 August, 2021, 12:25 pm
Last modified: 03 August, 2021, 12:29 pm
The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. Photo: Reuters
The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. Photo: Reuters

Sanofi said on Tuesday it has made a $3.2 billion offer to buy U.S. biotech company Translate Bio, as it bets on next-generation mRNA technology after setbacks in the Covid-19 vaccine race, confirming a Reuters exclusive report.

Sanofi said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion for Translate Bio. The boards of both companies have approved the deal, it said.

"Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics," Sanofi Chief Executive Paul Hudson said in a statement.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Translate Bio's shares surged on Monday following the Reuters report. Sanofi's offer of $38 represents a 30.4% premium to Translate Bio's August 2 closing price of $29.15.

GROWING INTEREST IN MRNA TECHNOLOGY

Sanofi's bid for Translate Bio marks the latest interest by a large pharmaceutical company in mRNA technology, following its proven success in Covid-19 vaccines developed by Pfizer /BioNTech and Moderna.

The messenger RNA (ribonucleic acid) approach, an area of Translate Bio expertise, instructs human cells to make specific proteins that produce an immune response to a given disease.

Sanofi and Translate Bio have been working together since 2018 and joined forces last year to develop an mRNA-based Covid-19 vaccine. They expect interim results of their Phase I/II clinical trial in the third quarter.

The two companies are also looking at mRNA vaccines for several infectious diseases and in June started a Phase I trial evaluating a possible mRNA-based vaccine against seasonal influenza, building on Sanofi's expertise as one of the world's top flu vaccine makers.

TOUGH YEAR

Sanofi's interest comes after a tough year for the French drugmaker after falling behind rivals with less experience in the Covid-19 vaccine race, a major blow to CEO Paul Hudson who joined the company almost two years ago.

Sanofi warned last year its traditional, protein-based Covid-19 jab developed with GlaxoSmithKline showed an insufficient immune response in older people, delaying its launch until toward the end of 2021.

Hudson has also been under increasing pressure to reduce the company's dependence on its star eczema treatment Dupixent to boost earnings. Earlier this year, it agreed to fill and pack millions of doses of shots made by Pfizer/BioNTech, Johnson & Johnson and Moderna.

Translate Bio, set up in 2016, has not launched any drugs on the market but its clinical-stage pulmonary product using its mRNA platform is being tested as an inhaled treatment for cystic fibrosis in a Phase I/II clinical trial, its website says.

Top News / World+Biz

Sanofi

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Bangladesh can be a first choice for our investment: Chinese business leaders 
    Bangladesh can be a first choice for our investment: Chinese business leaders 
  • Atik Morshed. Photo: Collected
    ACC finds irregularities in Nagad; Atik Morshed, his wife may be questioned
  • Representational image. Photo: Reuters
    Remittance hits second-highest monthly record of $2.97b in May ahead of Eid

MOST VIEWED

  • Govt slashes June prices for diesel, petrol, octane
    Govt slashes June prices for diesel, petrol, octane
  • Photo: Courtesy
    IFIC Bank incurs Tk500cr loss in Jan-Mar
  • Infographic: TBS
    Govt targets Dec opening of Dhaka airport's 3rd terminal but Japanese consortium wants 2 more months
  • Mahmud Hasan Khan Babu. Photo: Collected
    Mahmud-led Forum panel wins BGMEA election
  • Indian Chief of Defence Staff General Anil Chauhan shares insights on how Operation Sindoor represents future wars at Shangri-la Dialogue in Singapore on Saturday, 31 May 2025. Photo: ANI via Hindustan Times
    India confirms losing fighter jets in recent conflict with Pakistan: Bloomberg
  • Illustration: TBS
    Tax-free income ceiling to be raised, slabs restructured

Related News

  • Novavax signs Covid-19 license deal with Sanofi, removes doubt about business viability
  • Healthcare companies Sanofi and GSK to seek Covid-19 vaccine regulatory approval
  • Beximco Pharma completes Sanofi acquisition
  • France's Sanofi halts work on mRNA Covid vaccine
  • Beximco Pharma inks Sanofi acquisition deal

Features

Photo: Collected

Slice, store, sizzle: Kitchen must-haves for Eid-ul-Adha 2025

9h | Brands
The wide fenders, iconic hood scoop and unmistakable spoiler are not just cosmetic; they symbolise a machine built to grip dirt, asphalt and hearts alike. PHOTO: Akif Hamid

Resurrecting the Hawkeye: A Subaru WRX STI rebuild

15h | Wheels
Babar Ali, Ikramul Hasan Shakil, and Wasfia Nazreen are leading a bold resurgence in Bangladeshi mountaineering, scaling eight-thousanders like Everest, Annapurna I, and K2. Photos: Collected

Back to 8000 metres: How Bangladesh’s mountaineers emerged from a decade-long pause

2d | Panorama
Photos: Courtesy

Behind the looks: Bangladeshi designers shaping celebrity fashion

2d | Mode

More Videos from TBS

Can India replace China in world trade?

Can India replace China in world trade?

1h | Others
Chief Advisor–Party Meet: Consensus or Confrontation?

Chief Advisor–Party Meet: Consensus or Confrontation?

3h | Podcast
What did the BIDA Executive Chairman say about the China-Bangladesh Investment and Trade Summit?

What did the BIDA Executive Chairman say about the China-Bangladesh Investment and Trade Summit?

4h | TBS Today
News of The Day, 01 JUNE 2025

News of The Day, 01 JUNE 2025

5h | TBS News of the day
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net